B. Riley lowered the firm’s price target on PDS Biotechnology (PDSB) to $5 from $7 and keeps a Buy rating on the shares. The firm cites PDS01 f antibody drug conjugate triplet revenue contribution push out given the company’s heightened focus on securing Versamune HPV doublet path to market for the target cut.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PDSB:
- PDS Biotechnology Director Sir Richard Sykes Retires
- PDS Biotech’s Earnings Call Highlights: Clinical Progress Amid Funding Challenges
- PDS Biotechnology Advances Cancer Immunotherapy Trials
- PDS Biotechnology price target lowered to $13 from $21 at H.C. Wainwright
- Options Volatility and Implied Earnings Moves Today, March 27, 2025